Hepatitis C Vaccine Advances: New Nanoparticle Approach Shows Promise

Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, remaining a leading cause of cirrhosis and liver cancer. While direct-acting antiviral (DAA) medicines can cure most infections, global access remains limited, and these drugs do not prevent reinfection. Researchers are now focusing on developing a durable vaccine, a challenge complicated by the virus’s ability to evade immune detection.

The Challenge of Developing an HCV Vaccine

HCV evades immune detection using two distinct proteins that coat its surface, collectively known as the E1E2 glycoprotein complex. Historically, producing these proteins in a stable, native form—essential for vaccination—has proven exceptionally difficult. The E1 and E2 proteins tend to fall apart or misassemble when removed from the virus, hindering the creation of effective vaccine candidates.

New Research: Stabilizing the E1E2 Complex with Nanoparticles

A recent study published in Nature Communications on February 11, 2026, details a breakthrough by scientists at Scripps Research. They have engineered a native-like, stabilized version of HCV’s E1E2 complex and incorporated it into a nanoparticle-based vaccine candidate. This approach utilizes self-assembling protein nanoparticles (SApNPs), which organize multiple copies of the proteins into virus-like clusters, enhancing recognition by the immune system. https://www.nature.com/articles/s41467-026-69418-9

Rational Design and Structural Engineering

“Our lab focuses on all the major virus families, including those with surface proteins that are too unstable to utilize in traditional vaccines,” says senior author Jiang Zhu, a professor at Scripps Research. “For HCV, the central problem for decades has been that the two surface proteins, E1 and E2, fall apart or misassemble when removed from the virus. In this study, we were able to stabilize the native E1–E2 interface and generate a soluble complex that faithfully mimics the viral surface.”

The research team employed a structural engineering approach, designing a molecular scaffold to hold E1 and E2 together in their native orientation. They reinforced key contact points that normally cause instability outside the viral membrane, trimmed flexible regions that disrupted folding, and added protein scaffolds to lock the pair into the correct alignment. Electron microscopy confirmed the engineered proteins maintained their native structure.

Boosting Immune Response with SApNPs

Sixty copies of the stabilized proteins were displayed on the SApNP technology, mimicking the natural appearance of viruses and amplifying the body’s immune response. Testing in animal models showed the vaccine candidates triggered immune responses targeting the viral surface.

“The soluble, stabilized E1E2 complex serves as the foundation for this multivalent display, potentially enabling a vaccine format that was previously not feasible,” Zhu explains.

Expanding the Potential: Beyond a Single Vaccine

Zhu’s lab has extensive experience developing nanoparticle-based vaccines for various viruses, including HIV, influenza, Ebola, Sudan, and Marburg. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651911/ The success with HCV demonstrates the potential of this rational design approach. The stabilized E1 and E2 proteins also provide a valuable template for researchers developing both vaccines and antibody-based therapies.

“HCV was one of the most challenging given that it’s a very difficult vaccine target,” Zhu says. “Our rational design approach allowed us to first identify why the virus’ surface glycoproteins are so unstable, and then engineer solutions to overcome those challenges. Solving the soluble E1E2 problem removes a major bottleneck that has limited structure-based HCV vaccine design for decades.”

Future Directions

The team plans to refine the HCV vaccine candidates to enhance immune responses and evaluate their protective efficacy in future studies. Zhu is also exploring strategies to further improve the effectiveness of these vaccines. According to the World Health Organization, approximately 1.0 million new hepatitis C infections occur each year, highlighting the urgent need for preventative measures like a successful vaccine.

As of 2022, hepatitis C caused approximately 242,000 deaths globally, primarily from cirrhosis and liver cancer. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c